Canertinib Completed Phase 2 Trials for Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00051051A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer